Drug Profile
Research programme: aryl hydrocarbon receptor antagoinists - Hercules Pharmaceuticals
Alternative Names: CB 7993113Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Boston University
- Developer Hercules Pharmaceuticals
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Aryl hydrocarbon receptor antagonists; Cytochrome P-450 enzyme system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Viral infections
- No development reported Solid tumours; Triple negative breast cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Solid-tumours in Netherlands
- 20 Aug 2020 Preclinical trials in Viral infections in Netherlands (PO)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in Netherlands